AtaiBeckley (NasdaqGM:ATAI) 2026 Investor Day March 06, 2026 09:00 AM ET Company ParticipantsDavid Feifel - Founder and CEOKavita Pankey - Senior Vice President of New Product, Planning and CommercialKevin Craig - Chief Medical OfficerPeter Hendricks - ProfessorRyan Barrett - Chief Legal and Business OfficerSam Wilkinson - Associate Professor of PsychiatrySrini Rao - Co-founder and CEOOperatorAll right. Good morning, everyone, and thank you for joining us for AtaiBeckley's 2026 Investor Day. Before we begin ...

AtaiBeckley Inc (NASDAQ:ATAI) is among the 13 best NASDAQ penny stocks to buy according to analysts. On February 26, AtaiBeckley Inc (NASDAQ:ATAI) reported topline results from a Phase 2a trial of its drug candidate EMP-01 (oral R-MDMA), which is aimed for treating social anxiety disorder. According to AtaiBeckley, the study met its primary objectives, with EMP-01 showing efficacy signals with a favorable safe profile. In the US alone, social anxiety disorder is estimated to affect 30 million adults. The ...